Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Check source scope before reading a dose
Mozobil - BC Cancer Drug Manual
Product / population
BC Cancer guidance for adults receiving subcutaneous plerixafor for stem-cell mobilization.
Renal method
Calculated CrCl in mL/min, using the formula printed beneath the BC Cancer table.
All record notes are retained here, including notes about sources not selected in this review.
Mozobil - product and source limitations
BC Cancer specifies a renal weight-based regimen at CrCl 20-50 and provides no dose below 20 or on dialysis. Check the U.S. label and local transplant protocol separately.
What to reconcile: BC Cancer specifies a renal weight-based regimen at CrCl 20-50 and provides no dose below 20 or on dialysis. Check the U.S. label and local transplant protocol separately.
BC Cancer Drug Manual · BC Cancer guidance for adults receiving subcutaneous plerixafor for stem-cell mobilization.
Renal method: Calculated CrCl in mL/min, using the formula printed beneath the BC Cancer table. Source date: BC Cancer revision June 1, 2025. Retrieved: 2026-11-07
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Dosage Guidelines, adult renal and dialysis sections, page 4
For CrCl 20-50 mL/min, BC Cancer lists 0.16 mg/kg subcutaneously per day, with a 27 mg daily ceiling. The monograph gives no regimen below 20 or during dialysis. Its separate usual-dose weight table should not displace its renal instructions.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh Renal Dosing Master v7.4. Review the retrieval and revision dates attached to each source. Selecting a reference does not imply clinical verification.
